What is more, it has been detected that in melanoma patients a high CD20+ expression was connected with significant benefits caused by treatment with PD-L1/PD-1 pathway inhibition [54,55], so we can presume that in NMIBC patients this would be the same. The gene discussed is CD274; the disease is melanoma.